chromosomal translocation t9q34.1:22q11 (Philadelphia chromosome; bcr/abl)
Jump to navigation
Jump to search
Pharmacology
- antineoplastic agents imatinib (Gleevec), nilotinib (Tasigna) or dasatinib (Sprycel) should only be used in CML or AML patients with Philadelphia chromosome
Laboratory
Clinical significance
- t(9,22) occurs in association with chronic myeloid leukemia (CML)
- a truncated c-abl translocates from chromosome 9 to bcr locus on chromosome 22
- this occurs in approximately 90% of CML & 18% of ALL (L1 & L2)
- also found in AML
- the translocation results in formation of a chimeric bcr-abl oncogene
- the bcr-abl clone results in hyperexpansion of the myeloid clone with suppression of normal hematopoiesis
More general terms
Additional terms
- abl proto-oncogene
- acute lymphoblastic leukemia, L1
- acute lymphoblastic leukemia, L2
- breakpoint cluster region protein P160 (p160BCR)
- chromosomal translocation t(9;22)(q34.1;q11)(ABL1,BCR) in blood/tissue
- chronic myeloid leukemia (CML, granulocytic leukemia)
- p210 bcr/abl
References
- ↑ Cotran et al Robbins Pathologic Basis of Disease, W.B. Saunders Co, Philadelphia, PA 1989 pg 288
- ↑ Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 433
- ↑ Gleevec tablets [package insert]. East Hanover, NJ: Novartis Pharmaceuticals, Inc.; February 2010.
- ↑ Sprycel tablets [package insert]. Princeton, NJ: Bristol-Myers Squibb; June 2009.
- ↑ Tasigna capsules [package insert]. East Hanover, NJ: Novartis Pharmaceuticals, Inc.; June 2010
- ↑ The NCCN Chronic Myelogenous Leukemia Clinical Practice Guidelines in Oncology (Version 2.2010). 2010 National Comprehensive Cancer Network, Inc.
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015